Loading…
Aspire Biopharma Holdings, Inc. is projected to decline to $7.14 by 2027, a -1% move from its current price of $7.23. ASBP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $6.64 | $7.23 | $7.88 | +0.05% |
| Aug 6 | $6.41 | $7.24 | $8.17 | +0.10% |
| Aug 7 | $6.24 | $7.24 | $8.40 | +0.15% |
| Aug 8 | $6.10 | $7.24 | $8.60 | +0.20% |
| Aug 9 | $5.99 | $7.25 | $8.78 | +0.25% |
| Aug 10 | $5.88 | $7.25 | $8.94 | +0.30% |
| Aug 11 | $5.79 | $7.26 | $9.10 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.79 | $7.26 | $9.10 | +0.35% |
| Week 2 | $5.29 | $7.28 | $10.03 | +0.71% |
| Week 3 | $4.94 | $7.31 | $10.82 | +1.07% |
| Week 4 | $4.66 | $7.33 | $11.53 | +1.42% |
| Week 5 | $4.44 | $7.36 | $12.21 | +1.78% |
| Week 6 | $4.24 | $7.39 | $12.86 | +2.14% |
| Week 7 | $4.07 | $7.41 | $13.49 | +2.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company that develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. The company focuses on sublingual formulations, including a soluble, PH neutral, and fast acting sublingual aspirin product that addresses cardiology emergencies and pain management.
It is developing formulations for sublingually administered products such as melatonin sleep-aid, vitamins D, E, and K; testosterone; and semaglutide, among others. The company was founded in 2021 and is headquartered in Estero, Florida.
Aspire Biopharma Holdings, Inc. (ASBP) is the stock tied to a healthcare company focused on sublingual delivery technologies. The current price is $6.72 per share, with a market capitalization of $8.7M and a market rank of 4851. This places the stock in a micro-cap tier within the healthcare sector.
A major floor 97.9% below — a decisive break under it would weaken the trend.
The nearest floor, 26.1% below — buyers have tended to step in here.
The nearest ceiling, 7.3% above — a clean break opens room to run.
A major ceiling 23.9% above — clearing it would confirm fresh momentum.
Key ASBP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ASBP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.61 | Buy | $6.61 | Buy |
| MA 10 | $6.94 | Buy | $6.67 | Buy |
| MA 20 | $6.47 | Buy | $6.53 | Buy |
| MA 50 | $6.11 | Buy | $5.75 | Buy |
| MA 100 | $3.75 | Buy | $5.32 | Buy |
| MA 200 | $4.39 | Buy | $17.81 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.26 | Neutral |
| Stoch RSI (14) | 30.73 | Neutral |
| CCI (20) | 6.39 | Neutral |
| Williams %R (14) | -57.67 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | 7.95 | Buy |
| Bollinger %B (20,2) | 0.52 | Neutral |
| Stochastic %K (14) | 42.33 | Neutral |
| TRIX (15) | 0.73 | Buy |
| Awesome (5,34) | 0.32 | Buy |
| Ultimate (7,14,28) | 42.86 | Neutral |
| Momentum (10) | 0.28 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 6.19 | Buy |
| ADX (14) | 15.97 | Neutral |
| ATR (14) | 0.44 | Info |
The near-term technical picture shows bullish sentiment overall, with an RSI(14) of 50. The price is above the 50-day simple moving average at $6.09 and above the 200-day simple moving average at $4.42, signaling constructive momentum.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.155 | $7.23 | $11.16 | 0% | Neutral | |
| $5.20 | $7.14 | $10.59 | -1% | Neutral | |
| $5.08 | $7.41 | $11.72 | +2% | Neutral | |
| $4.18 | $6.42 | $10.68 | -11% | Neutral | |
| $3.73 | $6.02 | $10.43 | -17% | Bearish | |
| $4.18 | $7.05 | $12.63 | -3% | Neutral | |
| $4.52 | $7.95 | $14.69 | +10% | Neutral | |
| $5.29 | $9.68 | $18.40 | +34% | Bullish | |
| $5.30 | $10.11 | $19.70 | +40% | Bullish | |
| $4.41 | $8.73 | $17.42 | +21% | Bullish | |
| $5.62 | $12.50 | $27.41 | +73% | Bullish | |
| $8.00 | $17.78 | $40.90 | +146% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.155 | $7.23 | $9.30 | +0.00% |
| September 2026 | $6.07 | $7.38 | $9.36 | +2.11% |
| October 2026 | $6.14 | $7.57 | $9.80 | +2.56% |
| November 2026 | $6.61 | $8.24 | $10.83 | +8.80% |
| December 2026 | $6.64 | $8.37 | $11.16 | +1.59% |
Click any year to see its month-by-month ASBP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ASBP price prediction for 2026 points to an average of $7.23 (low $0.155, high $11.16) — a potential gain of 0% on today's $7.23. A consolidation phase looks the most probable path here.
In 2027, ASBP is projected to trade between $5.20 and $10.59, averaging $7.14 — a potential decline of -1% from today's $7.23. That is -1% versus the projected 2026 average. Price action looks broadly range-bound.
Aspire Biopharma Holdings, Inc.'s 2028 outlook centres on $7.41, within a $5.08 to $11.72 range. That is up +4% on the projected 2027 average. That marks a +2% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, ASBP could reach as high as $10.68, with a base case around $6.42 and support toward $4.18 — roughly -11% from $7.23. Price action looks broadly range-bound.
Expect ASBP to range from $3.73 to $10.43 through 2030. The $6.02 average target implies a -17% move from current prices. That is -6% versus the projected 2029 average. Expect choppier, lower action through this leg of the cycle.
The ASBP price prediction for 2031 points to an average of $7.05 (low $4.18, high $12.63) — a potential decline of -3% on today's $7.23. Price action looks broadly range-bound.
In 2032, ASBP is projected to trade between $4.52 and $14.69, averaging $7.95 — a potential gain of +10% from today's $7.23. That is up +13% on the projected 2031 average. A consolidation phase looks the most probable path here.
Aspire Biopharma Holdings, Inc.'s 2033 outlook centres on $9.68, within a $5.29 to $18.40 range. That is up +22% on the projected 2032 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2034, ASBP could reach as high as $19.70, with a base case around $10.11 and support toward $5.30 — roughly +40% from $7.23. Buyers look set to stay in control over this stretch.
Expect ASBP to range from $4.41 to $17.42 through 2035. The $8.73 average target implies a +21% move from current prices. That is -14% versus the projected 2034 average. Momentum favours further upside here.
The ASBP price prediction for 2040 points to an average of $12.50 (low $5.62, high $27.41) — a potential gain of +73% on today's $7.23. Buyers look set to stay in control over this stretch.
In 2050, ASBP is projected to trade between $8.00 and $40.90, averaging $17.78 — a potential gain of +146% from today's $7.23. That is up +42% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ASBP today (≈ 138.312586 ASBP) could be worth
$2,459.75
+$1,459.75 (+146%) by 2050 · US Dollar
Based on the average projected ASBP price of $17.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ASBPwould be worth at today's price.
$1,000 invested in ASBP on Jul 31, 2025 (≈ 65.616799 ASBP) would be worth
$474.41
-$525.59 (-52.6%) today · 0.47× · US Dollar
Based on a ASBP entry price of $15.24 vs. today's $7.23.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.26 | $995.87 | -0.4% |
| 1 month ago | $5.86 | $1,233.79 | +23.4% |
| 3 months ago | $0.212 | $34,103.77 | +3310.4% |
| 6 months ago | $1.7 | $4,252.94 | +325.3% |
| 1 year ago | $15.24 | $474.41 | -52.6% |
| All time (4.3y) ago | $399.6 | $18.09 | -98.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ASBP forecast.
Our base-case forecast reaches $14.00 around 2050.
Implied market cap at $14.00: $18.13M
The multi-year forecast presents a broad price path with notable volatility. In 2026 the average price is $6.72 with a 0% ROI and NEUTRAL sentiment, while 2030 shows a bearish tone with an average of $5.59 and a -16.8% ROI. Later years turn more bullish, with 2033 average $9.05 and 34.6% ROI, 2034 average $9.48 and 41.1% ROI, and a strong upside by 2040 with average $11.73 and 74.6% ROI, culminating in 2050 average $16.44 and 144.7% ROI.
The forecast also provides risk by year, including lower ranges in some years and higher upside in others; these figures are estimates, not guarantees.
Tap a question to reveal the answer.
The forecast for 2030 lists min $3.47, avg $5.59, max $9.69 with ROI -16.8% and sentiment BEARISH.
Near-term figures show 2026 avg $6.72 with ROI 0 and NEUTRAL sentiment. Longer term, 2040 avg $11.73 with ROI 74.6% and 2050 avg $16.44 with ROI 144.7%, indicating upside potential but with uncertainty.
The forecast shows higher upside in certain years, with 2033 avg $9.05 and max $17.20, 2034 max $18.48, and 2035 max $16.00, suggesting that $15 is within projected upside in some years.
For 2040, the forecast lists min $5.28, avg $11.73, max $25.74, with ROI 74.6% and sentiment BULLISH.
For 2050, the forecast lists min $7.40, avg $16.44, max $37.82, with ROI 144.7% and sentiment BULLISH.
Aspire Biopharma Holdings, Inc. Community Discussion
0Share your Aspire Biopharma Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.